{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:51:18Z","timestamp":1791143478152,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T00:00:00Z","timestamp":1398643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report the long\u2010term outcome of neurologic involvement in patients with Beh\u00e7et's disease (BD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective analysis of 115 patients who fulfilled the international criteria for BD (57% male; median age 37 years [interquartile range (IQR) 30\u201346 years]) and had neuro\u2010BD (NBD) after exclusion of cerebral venous thrombosis. Factors associated with relapse of NBD, inability to perform activities of daily living, and mortality were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy\u2010eight patients (68%) presented with acute NBD and 37 (32%) presented with a progressive course. The HLA\u2013B51 allele was carried by 49% of the patients. Overall, 46 of 115 patients (40%) had severe disability at baseline, represented by a Rankin score of \u22653. The 5\u2010 and 7\u2010year event\u2010free survival rates were 65% and 53%, respectively. In multivariate analysis, a positive HLA\u2013B51 status was independently associated with the risk of NBD relapse, with an odds ratio (OR) of 3.6 (95% confidence interval [95% CI] 1.5\u20139.1). After a median followup of 73 months (IQR 59\u2013102 months), 29 patients (25.2%) became dependent (were unable to perform activities of daily living) or died. Factors independently associated with poor outcome were paresis at onset (OR 6.47 [95% CI 1.73\u201324.23]) and location of inflammatory lesions at the brainstem on magnetic resonance imaging (OR 8.41 [1.03\u201368.43]). All 115 patients were treated with corticosteroids; 53 (46.1%) also took cyclophosphamide and 40 (34.8%) also took azathioprine. A trend toward longer event\u2010free survival was observed in patients with severe NBD (i.e., with a Rankin score of \u22653 at onset) receiving intravenous cyclophosphamide compared with those receiving azathioprine (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that NBD is a severe condition in which patients with the HLA\u2013B51 allele appear to experience a worse prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.38351","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T10:14:26Z","timestamp":1389176066000},"page":"1306-1314","source":"Crossref","is-referenced-by-count":122,"title":["Long\u2010Term Outcome of Neuro\u2010Beh\u00e7et's Disease"],"prefix":"10.1002","volume":"66","author":[{"given":"Nicolas","family":"Noel","sequence":"first","affiliation":[{"name":"APHP Groupe Hospitalier Piti\u00e9 Salp\u00e9tri\u00e8re, and DHU Inflammation, Immunopathologie, Bioth\u00e9rapie, Universit\u00e9 Pierre et Marie Curie, Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Bernard","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital St. Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Wechsler","sequence":"additional","affiliation":[{"name":"APHP Groupe Hospitalier Piti\u00e9 Salp\u00e9tri\u00e8re, and DHU Inflammation, Immunopathologie, Bioth\u00e9rapie, Universit\u00e9 Pierre et Marie Curie, Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Resche\u2010Rigon","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital St. Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Depaz","sequence":"additional","affiliation":[{"name":"AP\u2010HP, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du","family":"Le Thi Huong Boutin","sequence":"additional","affiliation":[{"name":"APHP Groupe Hospitalier Piti\u00e9 Salp\u00e9tri\u00e8re, and DHU Inflammation, Immunopathologie, Bioth\u00e9rapie, Universit\u00e9 Pierre et Marie Curie, Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Charles","family":"Piette","sequence":"additional","affiliation":[{"name":"APHP Groupe Hospitalier Piti\u00e9 Salp\u00e9tri\u00e8re, and DHU Inflammation, Immunopathologie, Bioth\u00e9rapie, Universit\u00e9 Pierre et Marie Curie, Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Drier","sequence":"additional","affiliation":[{"name":"AP\u2010HP, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Dormont","sequence":"additional","affiliation":[{"name":"AP\u2010HP, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[{"name":"APHP Groupe Hospitalier Piti\u00e9 Salp\u00e9tri\u00e8re, and DHU Inflammation, Immunopathologie, Bioth\u00e9rapie, Universit\u00e9 Pierre et Marie Curie, Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[{"name":"APHP Groupe Hospitalier Piti\u00e9 Salp\u00e9tri\u00e8re, and DHU Inflammation, Immunopathologie, Bioth\u00e9rapie, Universit\u00e9 Pierre et Marie Curie, Paris VI Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411707"},{"key":"e_1_2_7_3_1","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","author":"International Study Group for Beh\u00e7et's Disease","year":"1990","journal-title":"Lancet"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.05.029"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1982.01030040433013"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.625"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2551"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker428"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520390031011"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.11.2171"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.11.2183"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150170242"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5454-2"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2010.08.003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4800(03)80004-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24393"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00596576"},{"key":"e_1_2_7_18_1","first-page":"1015","article-title":"CNS involvement in neuro\u2010Beh\u00e7et syndrome: an MR study","volume":"20","author":"Kocer N","year":"1999","journal-title":"AJNR Am J Neuroradiol"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01754.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker449"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000258355.23810.c6"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0533-5"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24642"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.1999.540301.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000247169"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27568"},{"key":"e_1_2_7_27_1","first-page":"327","article-title":"HLA B51 antigen associated with neutrophil hyper\u2010reactivity","volume":"9","author":"Sensi A","year":"1991","journal-title":"Dis Markers"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380321"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.09.041"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/crad.2000.0675"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.7.793"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1414-6"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080432"},{"key":"e_1_2_7_35_1","first-page":"1355","article-title":"Value of \u201cbolus\u201d cyclophosphamide injections in Beh\u00e7et's disease: experience of 17 cases","volume":"19","author":"Du LT","year":"1990","journal-title":"Presse Med"},{"key":"e_1_2_7_36_1","first-page":"438","article-title":"Bolus of cyclophosphamide and methylprednisolone in uveitis in Beh\u00e7et's disease: preliminary results with the use of new criteria of evaluation","volume":"143","author":"Hamza M","year":"1992","journal-title":"Ann Med Interne (Paris)"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002013220501"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400425"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(98)00165-8"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23345"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem034"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38351","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:59:47Z","timestamp":1759946387000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,28]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1002\/art.38351"],"URL":"https:\/\/doi.org\/10.1002\/art.38351","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,28]]}}}